DBVT vs. VXRT, MOLN, CRDL, VIGL, OMGA, LIFE, SCLX, SGMO, BLUE, and CRDF
Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Vaxart (VXRT), Molecular Partners (MOLN), Cardiol Therapeutics (CRDL), Vigil Neuroscience (VIGL), Omega Therapeutics (OMGA), aTyr Pharma (LIFE), Scilex (SCLX), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), and Cardiff Oncology (CRDF). These companies are all part of the "biological products, except diagnostic" industry.
DBV Technologies (NASDAQ:DBVT) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
DBV Technologies has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
DBV Technologies has higher revenue and earnings than Vaxart. DBV Technologies is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
DBV Technologies has a net margin of -461.32% compared to Vaxart's net margin of -1,117.56%. DBV Technologies' return on equity of -46.33% beat Vaxart's return on equity.
71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 18.1% of Vaxart shares are owned by institutional investors. 0.6% of DBV Technologies shares are owned by company insiders. Comparatively, 3.0% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
DBV Technologies received 90 more outperform votes than Vaxart when rated by MarketBeat users. However, 65.47% of users gave Vaxart an outperform vote while only 57.25% of users gave DBV Technologies an outperform vote.
DBV Technologies presently has a consensus price target of $3.33, suggesting a potential upside of 397.51%. Vaxart has a consensus price target of $3.00, suggesting a potential upside of 310.96%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Vaxart.
In the previous week, DBV Technologies had 8 more articles in the media than Vaxart. MarketBeat recorded 11 mentions for DBV Technologies and 3 mentions for Vaxart. DBV Technologies' average media sentiment score of 0.23 beat Vaxart's score of 0.20 indicating that DBV Technologies is being referred to more favorably in the media.
Summary
DBV Technologies beats Vaxart on 12 of the 17 factors compared between the two stocks.
Get DBV Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DBV Technologies Competitors List
Related Companies and Tools
